Andrea Piacentini
Milan, 20148, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 14, 2025
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.
Journal: Pituitary
Published: May 21, 2025
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
Journal: European journal of endocrinology
Published: April 25, 2025
Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies.
Journal: Pituitary
Published: December 12, 2024
Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).
Journal: Endocrine journal
Published: August 25, 2024
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol.
Journal: Journal of the Endocrine Society
Published: July 15, 2024
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.
Journal: Frontiers in endocrinology
Published: June 30, 2023
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Journal: Journal of endocrinological investigation
Published: June 08, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026